Comparative Pharmacology
Head-to-head clinical analysis: KAPVAY versus LUCEMYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAPVAY versus LUCEMYRA.
KAPVAY vs LUCEMYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and blood pressure.
LUCEMYRA (lofexidine) is a central alpha-2 adrenergic agonist that reduces the release of norepinephrine in the brain, thereby alleviating opioid withdrawal symptoms.
0.1 mg orally twice daily, may increase by 0.1 mg/day at weekly intervals; maximum 2.4 mg/day in divided doses.
18 mg orally 5-6 times daily (maximum 108 mg/day) for 7-14 days then tapered over 4-6 weeks.
None Documented
None Documented
Terminal elimination half-life 12-16 hours (range 6-24 h) in adults; prolonged in renal impairment (up to 41 h) and in neonates.
Terminal half-life approximately 5-6 hours; no clinically significant accumulation with twice-daily dosing.
Renal: 40-60% unchanged; fecal: minimal (<10%); biliary: negligible.
Renal: 63% as unchanged drug; fecal: 27% (mostly unchanged); biliary: minimal (<5%).
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist